Chiral CuxCoyS Supraparticles Ameliorate Parkinson's Disease

Protein aggregation causes alpha-synuclein (alpha-syn) to change from its original physiological role to a pathological state, which is a potential pathogenic mechanism in Parkinson's disease (PD). Chiral L/D-CuxCoyS supraparticles (L/D-SPs) with a circular dichroism value of 35 mdeg at 805 nm were fabricated using a simple wet-chemical method. The L/D-SPs prevented the alpha-syn monomers from forming fibrils and triggered the alpha-syn fibrils to turn into monomers under 808 nm near-infrared (NIR) light. In living MN9D cells, D-SPs reduced cellular damage, neuronal functional deficits, and neuron loss caused by alpha-syn fibrils after NIR spectroscopy treatment within 10 min to prevent alpha-syn aggregation. Significantly, the reactive oxygen species produced by D-SPs were 1.42 times higher than those produced by L-SPs. In vivo experiments showed that D-SPs had a protective effect on neuron damage caused by alpha-syn aggregate deposition, reduced the symptoms in a mouse model of PD, and restored cognitive ability. After NIR light treatment, the amount of alpha-syn in a mouse model of PD decreased by more than 67.5%. At the same time, D-SPs gradually decomposed into small nanoparticleswithin 60 days and were excreted through the blood-brain barrier. This discovery paves theway for the treatment of neurodegenerative diseases using chiral SPs under NIR light irradiation. [GRAPHICS] .

Automated summary

Protein aggregation is a potential pathogenic mechanism in Parkinson's disease. Chiral supraparticles with circular dichroism were found to prevent and reverse protein aggregation, alleviating the symptoms of Parkinson's disease and being excreted through the blood-brain barrier.